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Abstract
Renal cell carcinomas (RCC) are emerging as a complex set of diseases with major socioeconomic
impact and a continued rise in incidence throughout the world. As the field of urologic oncology
faces these trends, several major genomic and mechanistic discoveries have altered our core
understanding of this multitude of cancers, including several new rare subtypes of renal cancers.
This review will examine these new findings, and place them in the context of the well-established
association of clear cell RCC (ccRCC) with mutations in the von Hippel-Lindau (VHL) gene and
resultant aberrant hypoxia inducible factor (HIF) signaling. The impact of novel ccRCC-
associated genetic lesions on chromatin remodeling and epigenetic regulation is explored. The
effects of VHL mutation on primary ciliary function, extracellular matrix homeostasis, and tumor
metabolism are discussed. VHL proteostasis is reviewed, with the goal of harnessing the
proteostatic machinery to refunctionalize mutant VHL. Translational efforts using molecular tools
to understand discriminating features of ccRCC tumors and develop improved prognostic and
predictive algorithms are presented and new therapeutics arising from the earliest molecular
discoveries in ccRCC are summarized. By creating an integrated review of the key genomic and
molecular biological disease characteristics of ccRCC and placing these data in the context of the
evolving therapeutic landscape, we intend to facilitate interaction between basic, translational and
clinical researchers involved in the treatment of this devastating disease, and accelerate progress
towards its ultimate eradication.
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A rapid series of discoveries in ccRCC, bolstered by advances in genomic biology and the
embrace of targeted therapy have ushered in a new era of biological investigation and
therapeutic opportunity for this challenging disease. ccRCC is unresponsive to traditional
chemotherapies, highly radiation resistant, and lacks the hallmark genetic features of solid
tumors such as KRAS or TP53 mutations. The unique tight association between ccRCC and
mutations in the VHL gene, and the resulting constitutive stabilization of hypoxia inducible
factors (HIF-1α and HIF-2α), have been a source of intense study over the past nearly two
decades. Stemming directly from the studies of VHL insufficiency is an enhanced
understanding of the intricate relationship between this tumor type and the tumor endothelial
vascular network, and the result has been the development of therapies which not only
reduce tumor burden, but also have extended the natural life expectancy of patients with
metastatic disease.
This review will examine recent developments poised yet again to produce a paradigm shift
in our understanding of the biology of ccRCC and other tumors, as well as to generate a
landscape ripe for development of new therapeutics. An international panel of experts
provides a concise description of the most relevant developments in their field for ccRCC.
Andy Futreal summarizes the discoveries arising out of the deep sequencing studies
performed over the last few years, and Ian Davis and Cheryl Walker describe the impact of
these mutations on cellular behaviour. The potential consequences of this finding are
enormous, and provide an explanation for the source of tumor heterogeneity as well as a
target for therapeutic intervention. Understanding of the VHL gene and HIF signaling
continues to evolve as well. Pathways are never as simple as they initially appear, and the
intense focus on HIF-1a signaling associated with VHL mutation has gradually shifted to a
focus on HIF-2α as the offending culprit in this disease, with definitive evidence now
available. Sean Bailey and William Kim describe these findings in more detail.
RCC is increasingly being recognized as a metabolic disease, and key lesions in nutrient
sensing and processing have been detected. These metabolic abnormalities provide
protection for the tumor but also may provide a source of vulnerability and therapeutic
opportunity. James Brugarolas and Amato Giaccia describe this important network. The
same is true for the recently described abnormalities in extracellular matrix engendered by
loss of VHL function, which are elucidated by Ghada Kurban and Arnim Pause. VHL is
increasingly being recognized as an important regulator of the primary cilium, and by
extension, of the cilia centrosome cycle. A better understanding of the role VHL plays in
this pathway can potentially lead to insights in RCC carcinogenesis. Cheryl Walker provides
a summary of this complex and intriguing function.
It has been well established that VHL mutations lead to malfolded, and poorly functioning
VHL protein. A better understanding of VHL proteostasis may allow us to develop
strategies to refold or otherwise refunctionalize point mutated, full length VHL. Eric
Jonasch and Judith Frydman report on recent developments in this emerging field.
Numerous biomarkers have emerged to clarify the presence of heterogeneity among tumors
that can be exploited for prognostic value or intervention. Kimryn Rathmell reviews the
emergence of molecular classification for RCC, and Amado Zurita describes prognostic and
predictive biomarkers under development. Finally, the goal of all of this outstanding science
is to allow us to offer patients better chances for survival and more healthy lives. The
therapeutic options for ccRCC have evolved rapidly in the last six years, and continue
unabated. Both targeted therapies directed at features uncovered in molecular and genetic
studies, and improved opportunities to re-direct the immune system have significant
potential to continue to improve the outlook for ccRCC. Brian Rini describes current and
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emerging molecularly targeted agents, and Pam Sharma and Michael Atkins review the
exciting new developments in immunotherapy for RCC.
GENETICS
Renal cell carcinoma (RCC) is a collective term applied to a set of cancers arising in the
epithelium of the renal tubules comprised of three main histopathological entities. Clear cell
RCC (ccRCC) is the dominant histology, accounting for approximately 65% of reported
cases, followed by papillary and chromophobe RCC, accounting for approximately 15–20
and 5%, respectively. Other more rare subtypes make up the remainder of RCC cases
including collecting duct, mucinous tubular, spindle cell, renal medullary, and MiTF-TFE
translocation carcinomas.
Hereditary RCC, which accounts for around 4% of cases, has been a relatively dominant
area of RCC genetics. Causative genes have been identified in several familial cancer
syndromes that predispose to RCC including VHL mutations in von Hippel-Lindau disease
that predispose to ccRCC[1], MET mutations in familial papillary renal cancer[2], FH
(fumarate hydratase) mutations in hereditary leiomyomatosis and renal cell cancer that
predispose to papillary RCC[3] and FLCN (folliculin) mutations in Birt-Hogg-Dubé
syndrome that predispose to primarily chromophobe RCC[4]. In addition, germline
mutations in the TSC1/2 genes predispose to tuberous sclerosis complex where
approximately 3% of cases develop ccRCC[5] and SDHB (succinate dehydrogenase type B)
germline mutations in patients with paraganglioma syndrome give rise to increased risk of
developing multiple types of RCC[6]. Moving away from rare monogenic disease to
population-based RCC susceptibility, genome wide association study results from a recent
study of almost 6000 RCC cases has implicated loci on 2p21 and 11q13.3 in RCC
susceptibility[7]. 2p21 contains the EPAS1 gene encoding a transcription factor operative in
hypoxia-regulated responses while the other region has no known coding genes.
There has been, however, comparatively less progress in the elaboration of the somatic
genetics of sporadic RCC. By far, the most studied somatically mutated gene is VHL, which
follows the classic tumor suppressor gene paradigm of a germline cancer susceptibility gene
also manifesting as being somatically mutated in the sporadic form of cancer type[8]. VHL
is somatically mutated in up to 80% of ccRCC[9]. The majority of these mutations are
protein-terminating mutations with loss of the wild-type allele via large-scale loss of
heterozygosity of chromosome 3p. There is a further small proportion (5–10%) of cases with
no apparent somatic mutations that apparently methylate the locus and thus are functionally
VHL null[9–11]. Along a similar theme of congruence of germline and somatic genetics,
albeit with a diminished magnitude of effect, there are dominantly activating kinase domain
MET mutation reported in 4–10% of sporadic papillary RCC[2]. Conversely, somatic
mutations in FLCN in chromophobe RCC are rare[12] and somatic FH mutations in sporadic
papillary renal cancers were not found [12–14]. Similarly, somatic mutations of TSC12 and
SDHB were not identified in sporadic RCC [13, 14]. Recently however, somatic mutations
in TSC1 have been found in sporadic ccRCC [15]. TSC1 mutations occur in 5% of ccRCCs
and may predict for extraordinary sensitivity to mTORC1 inhibitors clinically [15].
Further investigation of RCC somatic genetics has included evaluation of cancer genes
important in other adult epithelial cancers. Taking all histologies combined, the COSMIC
database reports somatic point mutations in TP53 in 10% of cases, KRAS/HRAS/NRAS
combined ≤1%, CDKN2A 10%, PTEN 3%, RB1 3%, STK11/LKB1 ≤1%, PIK3Ca ≤1%,
EGFR 1% and BRAF ≤1% (http://www.sanger.ac.uk/ genetics/CGP/cosmic/). MYC has
been reported to be amplified in papillary RCC [16] and rare cases of RCC have been
reported with EGFR amplification [17]. Focusing on the most prevalent histology, ccRCC,
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the contribution of cancer genes commonly mutated in other tumor types provides limited
insight into what additional somatic genetic events are contributing to pathogenesis.
With this as a background, systematic approaches have been undertaken to elaborate the
somatic genetics of ccRCC. A screen of 3,544 protein coding genes via PCR-based exon re-
sequencing in 101 cases of ccRCC identified several new cancer genes in RCC [18, 19].
Remarkably, four out of five genes with robust statistical support for being new cancer
genes encode proteins involved in histone methylation/demethylation. Truncating mutations
were identified in KDM6A/UTX, SETD2 and KDM5C/JARID1C which encode an histone
3 lysine 27 (H3K27) demethylase, an histone 3 lysine 36 (H3K36) methyltransferase and an
histone 3 lysine 4 (H3K4) demethylase, respectively. MLL2, an H3K4 methyltransferase,
was also mutated at a significant rate. These data implicate deregulation of histone H3,
known to be a major regulator of euchromatin/transcription, as a new area of RCC biology
for exploration. Of note and further confirming the utility of large-scale systematic
approaches, NF2 truncating mutations were unexpectedly identified in a significant
proportion of the small subset of ccRCC that are VHL wildtype. Taken together, however,
these genes are mutated in less than 15% of ccRCC suggesting the existence of additional
cancer genes.
A subsequent study has moved to solution capture and sequencing of the coding exons of
20,000 protein coding genes utilizing next-generation sequencing technologies to more
comprehensively investigate ccRCC somatic genetics. This work identified a second major
somatically mutated cancer gene in ccRCC and thus substantially reshaped the field of RCC
genetics. Truncating mutations in the PBRM1 gene were identified in a remarkable 41%
(92/227) of ccRCC [20]. PBRM1 encodes the Baf180 protein, a chromatin targeting subunit
of the SWI/SNF chromatin remodeling complex implicated in multiple chromatin/
transcriptionally mediated processes through interaction with histone H3 [21, 22],
reinforcing the striking theme of deregulated chromatin in ccRCC biology. Of note, VHL,
SETD2 and PBRM1 are all located on chromosome 3p, thus providing a likely explanation
for the near pathognomonic loss of 3p seen in ccRCC. Indeed, half of all cases with a
demonstrable VHL point mutation in this series have a PBRM1 truncating mutation and 9/9
cases with a SETD2 mutation also have concurrent VHL and PBRM1 mutations. This work
has framed important new areas for ccRCC basic and clinical research.
Recent work performing deep sequencing on samples from a variety of locations from
individual large tumors and metastatic lesions shows that considerable heterogeneity exists
within these tumors suggesting a branched pattern of evolution [23]. Mutational events, such
as the VHL mutation among others were ubiquitous to all samples, however, certain
mutations were present only in either the primary tumor or the metastatic lesions, and many
mutations were private. Of particular interest, different phylogenetic branches demonstrated
distinct SETD2 mutations, indicating a convergent pattern of selection for certain genotypic
events. More work to understand this process, and the implications for biomarker
development is needed.
Given the findings of these recent studies, it is a certainty that other RCC cancer genes and
driver mutations remain to be identified. To this end, there are international efforts
underway (ICGC www.icgc.org and TCGA cancergenome.nih.gov) to sequence large
numbers of RCC at the whole genome level, coupled with transcriptomic and epigenomic
analyses. This work is proceeding at pace, and thus the comprehensive structure of RCC
somatic architecture will be revealed in the coming few years.
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Together with long-standing insights into HIF deregulation through VHL loss, these
findings suggest that RCC development may represent a nexus of epigenetic and
transcriptional deregulation, and exploration of epigenetic modification could reveal critical
biological properties and offer clues to novel therapeutic approaches.
Genetic alterations in epigenetic regulators
As described above, high throughput genetic studies of RCC have identified recurrent
mutations in genes encoding several epigenetic regulators. Mutated genes have been
implicated in chromatin regulation through nucleosome repositioning and histone tail
modification. PBRM1, which was found to be mutated in nearly 40% of human RCC [20,
24], is a component of the Polybromo BRG1-associated factor complex (PBAF, SWI/SNF-
B). PBAF, like SWI/SNF, functions as a nucleosome remodeler and has been shown to be
involved in transcriptional regulation [25–27]. Less common mutations were also identified
in two methyltransferases, SETD2 and MLL2, and two demethylases, UTX (KDM6A) and
JARID1C (KDM5C) [18] (Figure 1). Deletion of 3p, a common finding in ccRCC
associated with the loss of VHL at 3p25 can also affect SETD2 and PBRM1, both at 3p21
[28]. SETD2 mediates the trimethylation of H3K36 [29], a histone mark that is placed
during transcription and may be important for maintaining faithful transcription [30, 31]
whereas MLL2 mediates H3K4me3, a mark associated with active transcription. UTX
demethylates H3K27me3 [32–34], a histone mark associated with repressed chromatin.
Interestingly, UTX associates with MLL2 [32, 35], suggesting that demethylation of
repressive marks is linked to placement of marks associated with transcriptional activation.
JARID1C demethylates H3K4 [36]. The finding of mutations in MLL2 and JARID1C,
which act oppositely on the same residue, suggests that the genomic effects of mutations in
these genes are likely to be complex (Figure 1). Although some mutations may result in
widespread epigenetic variation, the effect of others may demonstrate preference for specific
regions of the genome [37].
HIF- and hypoxia-mediated epigenetic regulation
The hypoxia response pathway has previously been shown to have a direct effect on histone
modification. HIF been shown to activate several chromatin demethylases, including
JMJD1A (KDM3A), JMJD2B (KDM4B), JMJD2C (KDM4C) and JARID1B (KDM5B), all
of which are directly targeted by HIF [38–41]. Re-expression of pVHL in VHL deficient cell
lines increased H3K4me3 levels associated with decreasing levels of JARID1C, a target of
HIF2α [24]. Silencing JARID1C in VHL-deficient tumor cells augmented tumor growth in a
xenografted mouse model suggesting that JARID1C acts as a tumor suppressor. In contrast,
hypoxia may increase methylation through HIF independent mechanisms. Like HIF prolyl
hydroxylase (EGLN3), histone demethylases are members of the dioxygenase superfamily,
which require oxygen as well as iron and 2-oxoglutarate for activity [42, 43]. In a manner
analogous to stabilization of HIF via decreased hydroxylation, hypoxia was shown to
suppress JARID1A (KDM5A) activity resulting in increased H3K4me3 levels [44]. This
suggests the hypothesis that loss of demethylases (and by analogy increased histone
methylation) is part of a “hypoxia phenotype” which is selected for in RCC. This “hypoxia
phenotype”, which is mimicked by VHL loss, would also be mimicked by loss of histone
demethylase activity, which as noted above, is a high-frequency event in RCC.
Chromatin organization also influences HIF function. Studies of HIF, induced under
conditions of hypoxia, demonstrated preferential targeting of HIF to previously nucleosome-
depleted chromatin regions [27]. Moreover, the co-expression of SWI/SNF components
BRG1, BAF170 and BAF57 augmented HIF activity from a HIF responsive reporter [26].
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This study demonstrated that BRG1, but not BRM silencing, decreased HIF responsiveness,
suggesting that PBAF may be more critical for HIF function than SWI/SNF.
To what extent mutations of epigenetic regulators influence chromatin or HIF targeting
remains unknown. Because of the direct influence of hypoxia on demethylase activity, it is
likely that the relationship between epigenetic variation and HIF targeting will differ under
conditions of hypoxia in primary cells and in the context of specific epigenetic alterations in
tumor cells. Altering the activity of an individual epigenetic regulator that functions as part
of a complex may result in pleiotropic effects resulting from alterations in the stoichiometry
of active complexes.
In addition to epigenetic regulation through histone tail modification, DNA methylation in
RCC has been well recognized. Through studies of tumors, urine and RCC-derived cell
lines, hypermethylation of several tumor suppressor genes have been demonstrated.
RASSF1 may be hypermethylated in over half of RCC with less common hypermethylation
of VHL and CDKN2A [10, 45–48]. Additional studies have identified methylation and
silencing of other genes include TIMP3 and secreted frizzled-related protein 2 ([49, 50]
[51]). The use of genome-wide assays of methylation and studies of differential methylation
will likely identify many more loci that are methylated in ccRCC [52, 53], however, the
relationship between DNA hypermethylation and histone modification in the context of
RCC remains unclear.
Therapeutic implications
Epigenetic differences may predict variation in patient outcome. Global decreases in H3K4
methylation and H3K18 acetylation have associated with decreased patient survival [37, 54].
Since epigenetic alterations and transcriptional deregulation are central to RCC, employing
agents with predicted epigenetic influences may have an effect on disease outcomes. In
preclinical studies, treatment with the histone deacetylase inhibitor vorinostat augmented the
activity of the mTOR inhibitor temsirolimus to induce apoptosis in xenografted RCC cell
lines [55]. However, a phase II trial of a different HDAC inhibitor, panobinostat, in patients
with refractory metastatic RCC failed to demonstrate an objective response [56]. A more
precise understanding of the role of epigenetic alterations could indicate other targetable
strategies.
HIFs AND HIF TARGET GENES
The hypoxia-inducible factors (HIF) are a family of transcription factors that contain a basic
helix-loop-helix domain and function in a heterodimeric complex [57]. There are three
known HIFα subunits (HIF-1α, HIF-2α, HIF-3α) which heterodimerize with their binding
partner ARNT (HIF-1β) to transcriptionally regulate target genes containing hypoxia
response elements (HREs). HIF-1α and HIF-2α, are best characterized and are known to
regulate transcriptional programs associated with cellular and physiological adaptation to
hypoxia such as erythropoietin (EPO), vascular endothelial growth factor (VEGF), and
carbonic anhydrase 9 (CA9), amongst others [58]. While there is significant overlap in genes
that are transcriptionally activated by HIF-1α and HIF-2α, each HIF family member is
thought to also transactivate unique target genes [59]. For example, HIF-1α has been linked
to regulating genes in pathways associated with glycolytic metabolism such as, SLC2A1
(GLUT1), LDHA and autophagy BNIP3 while HIF-2α is uniquely responsible for
transcriptionally activating genes associated with proliferation and de-differentiation, TGFα,
CCND1 (Cyclin D1), and Oct4, respectively.
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VHL regulation of HIF
An important realization in understanding the molecular pathogenesis of VHL deficient
RCC was that under conditions of normoxia, the pVHL complex binds to and
polyubiquitinates HIFα subunits, resulting in their targeting and destruction by the
proteasome[57]. The interaction between HIF and pVHL is mediated by an enzymatic, post-
translational hydroxylation of HIF on conserved prolyl residues by a family of HIF prolyl
hydroxylases (PHDs or EGLNs). In keeping with the notion that regulation of HIF is an
important function of pVHL, the majority of disease associated VHL mutations are
predicted to abolish the interaction between pVHL and HIF[60]. Moreover, studies in mice
suggest that HIF activation (in particular HIF-2α) mediate the majority of the phenotypes
seen in the setting of VHL loss [61–63].
Role of HIF in RCC
Early in vitro and cell line xenograft studies suggested that while HIF-2α is both necessary
and sufficient for the growth of transformed RCC cell lines [64–66] HIF-1α is not[67],
indicating that HIF-1α is expendable for RCC growth. However, it appears that HIF-1α is
not merely dispensable in the context of RCC but actually functions as a tumor suppressor
gene. Several lines of evidence support this hypothesis. First, targeted exon sequencing of
RCC has demonstrated (albeit rarely) inactivating mutations in HIF-1α, while copy number
analysis RCC cell lines and primary tumors suggest that the HIF-1α locus is frequently lost
along with the long arm of chromosome 14 (14q) [18, 68]. Secondly, while all VHL
defective clear cell renal cell carcinomas appear to overexpress HIF-2α, about one third of
these tumors appear to lack HIF-1α expression as well [69]. Finally, functional studies in
vitro and in vivo suggest that over expression of HIF-1α in VHL wild type cells restrains
tumor growth while suppression of HIF-1α in VHL deficient cells enhances tumor growth
[68, 70]. Together these studies show support for HIF-1α as tumor suppressor gene in renal
cancer development and HIF-2α as a key driver for renal cancer progression.
While there are a number of reasons to explain the contrasting properties of HIF-1α and
HIF-2α in RCC pathogenesis, one intriguing observation is that HIF-1α and HIF-2α have
opposing roles on the regulation of c-Myc activity. Specifically HIF-1α acts to suppress c-
Myc activity while HIF-2α promotes the transactivation or transrepression of c-Myc specific
target genes [59, 69, 71]. In keeping with this notion, RCC tumors that exclusively express
HIF-2α have increased proliferation rates. Furthermore, intriguingly, a subset of clear cell
RCC tumors appear to have copy number amplification of 8q24, where c-Myc resides [72].
VHL PROTEOSTASIS
Two pVHL isoforms exist in the cell, a 213 amino acid, 30 kilodalton form, and a 160
amino acid 19 kilodalton version[73]. In order to function, pVHL must fold to its native
conformation. Proper folding and functionality of pVHL requires its tight association with
elongin B and elongin C to give rise to a VHL-elongin BC complex (herein VBC). Failure
of pVHL to fold and to interact with elongin BC results in misfolding and proteolytic
degradation of pVHL [74]. This section summarizes pVHL protein homeostasis (also called
proteostasis), and how disease causing mutations affect pVHL stability and functionality.
Molecular chaperones are essential mediators of protein folding and quality control of most
proteins in the cell. Following synthesis on ribosomes, folding of functional pVHL protein is
the result of a complex interplay between nascent pVHL and cellular chaperones. Nascent
pVHL is shuttled from the ribosomal machinery with the assistance of heat shock protein 70
(HSP70)[75]. pVHL is then folded into its tertiary structure via association with the
chaperonin complex TRiC (for TCP-1 Ring Complex), also called CCT (chaperonin
containing TCP-1)[75–78]. This hetero-oligomeric complex consists of two stacked rings
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with a central chamber where unfolded polypeptides bind and fold. TRiC is responsible for
folding a number of key proteins that, like pVHL, are also subunits of oligomeric complexes
[76, 77, 79, 80]. Hsp70 likely functions to stabilize non-native forms of pVHL, while TRiC/
CCT facilitates pVHL folding, which is coupled to its incorporation into assembly of VBC
[81–83]. Upon VHL binding to elongin BC to form mature VBC, pVHL is released from
TRiC [75] (Figure 2).
Binding of VHL to TRiC occurs at amino acids 114–119 and 148–155, called Box 1 and
Box 2, respectively[84]. Both motifs, located in adjacent strands of the beta-domain, harbor
tumor-causing mutations that disrupt association with TRiC and lead to misfolding of newly
translated pVHL. Mutations that block pVHL incorporation into a well folded VBC complex
appear to result in destabilization and lower intracellular levels of pVHL, although residual
functionality is maintained in some cases [85]. Further analysis of how specific mutations
affect the interaction of pVHL with chaperones and chaperonins provides insight into
targetable mechanisms of pVHL protein destabilization. Disease causing mutations in TRiC
Box 1 and Box 2 binding sites [84, 86, 87], prevent association of pVHL to TRiC, resulting
in a malfolded protein, and the absence of a mature VBC complex in the cell. Disease
causing mutations also occur in the amino acid 155–181 elongin C binding region[86, 87].
This class of mutants can bind to TRiC, but cannot stably bind to elongin BC. Loss of
elongin C binding capacity appears to prevent pVHL release from TRiC [84], resulting in a
lack of mature VBC complex.
Failure to generate a properly folded pVHL or a mature VBC complex will result in pVHL
degradation through the ubiquitin-proteasome system. Chaperones are also involved in this
quality control process[84, 88]. pVHL degradation specifically requires another chaperone,
Hsp90, which does not participate in pVHL folding[88]. The identification of two distinct
pathways of chaperone interactions for pVHL, one leading to folding and one to
degradation, suggests that the fate of pVHL may be controlled by a hierarchy of chaperone
interactions. Understanding the mechanism of how destabilized pVHL mutants are targeted
for proteasomal degradation may lead to strategies of refolding and stabilization of pVHL
that is functional and competent to complex with elongins B and C. Bortezomib and MG132
are capable of increasing levels of VHL, and a cell-based Prestwick compound screen
identified several compounds that up-regulate point mutated VHL[89]. Efforts to analyze
functional consequences of pVHL upregulation using these compounds, as well as an
expanded screening effort are underway.
In summary, our evolving understanding of proteostasis allows new therapeutic approaches
to be developed for VHL disease. Recalibrating the interaction between point-mutated
pVHL and the chaperones and chaperonins may alter disease phenotype and provide benefit
for patients with lesions possessing either germline or sporadic VHL mutations.
RCC: ONE OF THE “CILIOPATHIES”
Together with Polycystic Kidney Disease (PKD), Tuberous Sclerosis Complex (TSC) and
VHL Syndrome are considered ‘ciliopathies’ [90]. In PKD, TSC2 and VHL deficiency,
renal cysts develop following loss of gene function, often as preneoplastic lesions. One of
the hallmarks of cysts is dysfunctional primary cilia. All cells possess a single primary
cilium, a non-motile organelle composed of a central microtubule axoneme anchored by the
basal body, surrounded by the ciliary membrane (Figure 3). In the kidney, the primary
cilium projects from the apical surface of renal epithelial cells into the kidney lumen, where
it responds to fluid flow and acts as a chemo-, osmotic, mechano-sensor of the environment.
Loss of primary cilia results in dysregulated cell signaling, cystogenesis in the kidney and
several other organs, and is one of the hallmarks of many types of cancer, including RCC.
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Several cell signaling pathways linked to tumorigenesis either localize specifically to the
primary cilium and/or are spatially regulated by this organelle, including Wnt, Hedgehog
and platelet-derived growth factor (PDGF) signaling [90, 91]. In addition to aberrant
signaling, the microtubule organizing center (MTOC) that forms the foundation for the
primary cilium, the basal body, also functions in the cell during mitosis as the centrosome
[92]. The fact that this MTOC must shuttle between functioning as a basal body for the
primary cilia and a centrosome for the mitotic spindle means that the cilia-centrosome cycle
must be tightly coupled to cell division to maintain genomic stability. The cilia-centrosome
cycle is important for maintaining genomic stability. Centrioles of the basal body, which
serve as the microtubule organizing center (MTOC) for the ciliary axoneme, also serve as
the MTOC for the mitotic spindle. There they function as the centrosome, which is
comprised of a pair of centrioles responsible for spindle formation during mitosis. Thus, the
centrioles serve two distinct and mutually exclusive functions in the cells, serving as the
MTOC for either the mitotic spindle (during M phase) or the primary cilium (during G0/
G1). The fact that this MTOC shuttles between these two functions means that the cilia-
centrosome cycle must be tightly regulated to guarantee the fidelity of centrosome
replication, spindle formation and genomic stability. Importantly, defects in cilia-
centrosome cycle checkpoints have the potential to cause inappropriate centrosome
replication, supernumerary centrosomes, and ultimately aneuploidy. Interestingly, it has
recently been shown that ,VHL localizes to the mitotic spindle in mammalian cells and
causes spindle misorientation and chromosomal instability when defective or absent [93]
pVHL, TSC and PKD-associated proteins also share a common function: regulation of the
structure and function of the primary cilium. These “renal cystoproteins” have been
localized at the primary cilium where they exert a variety of cellular responses [94, 95]. For
instance, PKD-1 plays a critical role at the primary cilium where it is involved in ciliary
mechanotransduction. Several studies have indicated that VHL is also involved in the
biogenesis and function of the primary cilia [94, 96, 97] and biallelic inactivation of this
gene is associated with loss of cilia [98]. Consistent with this observation, RCC of the clear
cell type, associated with loss of pVHL, shows markedly reduced cilia formation when
compared to papillary carcinoma [99]. In addition, pVHL binds to microtubules [93, 100],
and co-localizes with the acetylated tubulin in the cilia where its mobility is dependent on its
association with Kif3A [101]. Studies linking TSC2 deficiency to ciliary defects are more
recent where loss of TSC2 is linked specifically to the development of aberrant primary
cilia. This abnormal ciliary phenotype is also associated with loss of TSC1, which localizes
to the basal body [102].
REGULATION OF THE EXTRACELLULAR MATRIX
The extracellular matrix (ECM) is a complex structural component that surrounds the cells
and provides support. It is composed of proteoglycans, hyaluronic acid and glycoproteins
such as fibronectin and many types of collagens [103, 104]. Disruption of its regular
architecture has been associated with tumor growth, angiogenesis, and metastasis. pVHL
plays an important role in the regulation of the ECM. It was shown to interact directly with
fibronectin and collagen IV, resulting in their assembly into the ECM and suppression of
tumorigenesis, angiogenesis and cell invasion [105–109]. Most pVHL mutants fail to bind
and degrade HIF-α, however all pVHL mutants tested to date fail to bind fibronectin and
collagen IV and lose the ability to assemble an ECM [105–111]. The interaction of pVHL
with fibronectin is mediated by pVHL neddylation which acts as a molecular switch
conferring selectivity to fibronectin binding over CUL2 [109, 112], while its interaction with
collagen IV is dependent on endoplasmic reticulum (ER) hydroxylation [107]. The VHL-
collagen IV interaction was shown to occur at the ER membrane, with pVHL binding to a 70
kDa fragment of the collagen IV amino terminus that protrudes out of the ER into the
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cytosol [107]. The mechanistic significance of these interactions is still not clear but it was
shown that pVHL did not affect fibronectin and collagen IV production or secretion nor
resulted in collagen IV proteosomal degradation [106, 107].
The role of pVHL in ECM regulation is independent of its role in HIF-α regulation. Indeed,
it was shown that inactivation of the VHL-ECM assembly pathway results in tumors that are
highly vascularized, have a remodeled fibronectin and collagen IV matrix and show
increased invasive ability. Loss of the VHL-HIF-α regulation pathway resulted in tumors
with high VEGF levels but with decreased angiogenesis, a tightly assembled fibronectin and
collagen IV matrix and low invasive capacity. Therefore while both pathways cooperate in
supporting tumorigenicity, ECM remodeling may promote angiogenesis by providing a path
for blood vessels to infiltrate tumors [106].
Tumor cell invasion is dependent on adhesion and proteolytic remodeling of the ECM, both
of which are influenced by pVHL activity. pVHL was shown to regulate adhesion
molecules; its inactivation leads to downregulation of the adherens junction protein E-
cadherin and stimulation of invasion in RCC [113–115]. Loss of pVHL function also leads
to downregulation of tight junction proteins occludin and claudin, in an E-cadherin
independent manner [116]. In these studies, disruption of both adherens and tight junctions
were mediated by loss of the pVHL-HIF-α regulation pathway. In another study, pVHL was
found to downregulate integrins in a HIF-α independent manner and this correlated with
restoration of tight and adherens junctions [117]. Cells lacking pVHL also fail to form β1
fibrillar adhesions, possibly contributing to the increased cell motility and invasiveness seen
in the absence of a functional pVHL [118].
VHL pathways also regulate matrix metalloproteinases (MMPs), a family of matrix-
degrading enzymes involved in ECM turnover. RCC cell lines lacking pVHL showed
increased invasiveness in growth factor-reduced Matrigel, overproduced MMPs 2 and 9 and
displayed an extensive branching morphogenesis phenotype in response to hepatocyte
growth factor/scatter factor as compared to those with wild-type pVHL[119]. Activation of
MMPs upon loss of pVHL activity can be attributed to disruption of both VHL-ECM and
VHL-HIF-α pathways. Loss of VHL-ECM pathway regulation in RCC cells resulted in
increased cell invasiveness and activation of MMP-2 [106], and HIF-α was also shown to
influence RCC cell invasiveness by regulating membrane type-1 MMP expression [120,
121]. Proteolytic remodeling of the ECM by MMPs was shown to expose cryptic sites in
collagen IV, normally hidden within the triple helical structure, leading to loss of integrin
α1β1 binding and a gain of binding to the αvβ3 integrin, resulting in stimulation of
angiogenesis [122]. Antibodies directed towards collagen IV cryptic sites led to inhibition of
angiogenesis, tumor growth and metastasis in vivo suggesting the importance of collagen IV
matrix remodeling in these processes [122–125].
The role of pVHL in maintaining ECM integrity and suppression of tumorigenesis,
angiogenesis and invasiveness is multi-faceted and complex. It may result from interplay
between several mechanisms that still remain unresolved. It is possible that pVHL mediates
fibronectin and collagen IV modification, allowing their proper assembly into the ECM.
Loss of these interactions would lead to an aberrant ECM, activation of MMPs, ECM
remodeling, release of ECM sequestered growth factors and stimulation of tumorigenesis,
angiogenesis and invasion. Disruption of integrins and cell adhesion molecule regulation
would further enhance the invasive RCC phenotype. Understanding the mechanisms of
ECM regulation by pVHL could provide additional or alternate therapy for RCC patients
distinct from tyrosine kinase inhibitors.
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RENAL CELL CARCINOMA AND METABOLISM
An intimate link between metabolism and renal cancer was established by the discovery that
genes encoding enzymes of the Krebs cycle suppress tumor formation in kidney cells [126,
127]. The Krebs cycle refers to 9 sequential enzymatic reactions implicated in oxidizing
acetyl-CoA generated from glucose, fatty acids and amino acids to CO2 (Figure 4). This
cycle is essential to the process of mitochondrial ATP generation. Succinate dehydrogenase
(SDH), a complex of 4 different polypeptides (SDHA-D) that is also involved in electron
transfer, catalyzes the conversion of succinate to fumarate. Heterozygous germline
mutations in SDH subunits predispose to pheochromocytoma/paraganglioma and mutations
in SDHB and SDHD have also been associated with renal cell carcinoma (RCC) [6, 128].
Fumarate hydratase (FH) catalyzes the next reaction of the Krebs cycle, the conversion of
fumarate to malate. Heterozygous germline FH mutations cause hereditary leiomyomatosis
and renal cell cancer (HLRCC), a syndrome characterized by cutaneous and uterine
leiomyomas as well as RCC [3, 129]. RCCs occur in 20–50% of HLRCC families, are
typically papillary-type 2 (pRCC-2)[130], and tend to be very aggressive [131].
The FH and SDH genes function as two-hit tumor suppressor genes [55, 127]. Loss-of-
function mutations in the germline are usually accompanied by loss of heterozygosity
(LOH) in the tumor causing the truncation of the cycle and the accumulation of
intermediates [132, 133]. The accumulation of succinate or fumarate causes the inhibition of
a family of 2-oxoglutarate-dependent dioxygeneases normally implicated in HIF-α
hydroxylation [134–136]. In the absence of this modification, HIF-α evades recognition by
pVHL and accumulates, leading to increased HIF activity and tumor development [57]. In
addition, the accumulation of succinate and fumarate results in the succination of proteins,
including Keap1 [137, 138]. Keap1, is a component of an E3 ubiquitin ligase that targets
NRF2 for degradation, and its succination blocks NRF2 degradation resulting in its
accumulation and increased expression of stress-response and antioxidant genes [137–139].
Truncation of the Krebs cycle results in a compensatory increase in glucose uptake and
glycolysis[132, 140–142]. Accordingly, HLRCC-associated pRCC-2 are intensely FDG-
PET positive [142, 143]. Unlike other tumor cells, FH-deficient pRCC-2 cells are unable to
grow in low glucose concentrations [142]. This dependency on glucose offers an opportunity
for therapeutic intervention and we recently reported an attempt to treat an HLRCC patient
with advanced pRCC-2 refractory to mammalian target of rapamycin complex 1 (mTORC1)
inhibition with an inhibitor of glycolysis [143].
Metabolic derangements are also associated with mutations in VHL. Germline VHL
mutations predispose to clear-cell RCC (ccRCC) [1], referred to in this manner because of
the accumulation of lipid and glycogen which gives a clear appearance to the tumor cells in
the tissue after processing. By contrast to VHL, SDH and FH genes are seldom mutated in
the sporadic setting [12, 13]. Interestingly, while Vhl mutations do not cause RCC in the
mouse, disruption in the liver phenocopies the accumulation of lipid and glycogen observed
in ccRCC [61, 144–148]. Thus, hepatocytes may serve as a model to study the role of VHL
in metabolism. Acute Vhl disruption in hepatocytes results in a Hif-dependent inhibition of
mitochondrial respiration [148]. Deprived of Vhl, glucose and ketone production by
hepatocytes drops and the mice die within days [148]. While the relative contribution of
Hif-1 and Hif-2 remains to be fully determined, Hif-2 may play an important role [147–
149]. Should a similar inhibition of mitochondrial respiration occur in ccRCC, these tumors
may be exquisitely sensitive to glycolysis inhibitors.
Vulnerabilities arising from VHL loss in ccRCC are also being exploited through synthetic
lethal screens [150, 151]. This was illustrated genetically by screening VHL-deficient
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ccRCC cell lines with shRNAs against kinase targets. This screen identified several kinases
synthetic lethal with VHL including cyclin-dependent kinase 6 (CDK6), hepatocyte growth
factor receptor (MET), and dual specificity mitogen-activated protein kinase kinase 1
(MEK1) [151]. Small molecule inhibitors of CDK6 also proved to reduce the viability of
VHL-deficient ccRCC tumor cells [151]. In addition to the shRNA approach, small
molecule screening has also been fruitful in identifying new targets exhibiting enhanced
cytotoxicity against VHL-deficient ccRCC. The compound STF-62247 significantly reduced
the survival of VHL-deficient ccRCC in cell culture as well as in transplanted tumors in
immunodeficient mice. STF-62247 induces autophagy and disrupts Golgi trafficking, which
in VHL-deficient cells leads to cell death [150]. From the same screen, a second compound,
STF-31, was identified that also exhibits enhanced cytotoxicity against VHL-deficient
ccRCC. STF-31 inhibits glucose uptake by the Glut-1 transporter and induces necrotic cell
death in VHL-deficient ccRCC [152]. This small molecule provides evidence that targeting
glucose metabolism directly in VHL-deficient ccRCC could provide a therapeutic gain
clinically.
Another pathway implicated in RCC pathogenesis and which plays an important role in
metabolism is the mTORC1 pathway (Figure 5). mTORC1 is the target of two FDA
approved drugs, temsirolimus and everolimus, and is a master regulator of cell growth.
mTORC1 integrates environmental and cellular cues with the cell growth machinery [153].
Signals from energy stores [154], oxygen [155] and growth factors [156] are largely
transduced to mTORC1 through a protein complex formed by the proteins tuberous sclerosis
complex 1 and 2 (TSC1/TSC2). By contrast, nutrients regulate the subcellular localization of
mTORC1 [157]. Only in the presence of nutrients is mTORC1 receptive to signals funneled
through TSC1/TSC2 [160, 161]. The best characterized function of mTORC1 is in
promoting protein translation, a process mediated, at least in part, by the phosphorylation of
S6K and the eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) [158, 162, 163].
However, mTORC1 plays also an important role in suppressing autophagy [159, 163] and
regulating mitochondria [164]. In addition, several transcription factors are regulated by
mTORC1. mTORC1 regulates HIF-1 [165–170] coupling thereby trophic functions to
angiogenesis. mTORC1 also regulates sterol regulatory element binding protein1 (SREBP1),
a master regulator of lipogenesis [171, 172]. Finally, we recently reported that mTORC1
regulates the transcription factor EB (TFEB)[173], a controller of lysosome biogenesis
[174]. Interestingly, the TFEB gene is translocated in a subset of RCCs [175, 176] and the
regulation of TFEB by mTORC1 may provide opportunities for therapeutic intervention.
DEFINING NEW MOLECULAR SUBTYPES OF RCC
It has become increasingly clear that ccRCC is an incredibly heterogeneous disease. We
have learned only in recent years how thoroughly distinct are the differences between
ccRCC and non-clear cell histologies, that they in fact may be best served to be considered
as different diseases, with distinct biology, prognosis, and response to treatment [177–180,
181, 182]. Indeed, even within the less common papillary type RCC, two distinct subtypes
emerge, papillary types 1 and 2 [183–188]. These two papillary subtypes are associated with
distinct familial syndromes: hereditary papillary RCC (associated with type 1 papillary
RCC), caused by germline mutations in the Met proto-oncogene [2], and hereditary
leiomyosarcoma and RCC (HLRCC, associated with type 2 papillary RCC) [129], in this
case fumarate hydratase, are discussed above. The underlying genetic events in sporadic
versions of these two histologically defined subtypes are undergoing investigation.
Within the category of clear cell RCC, heterogeneity has also been widely appreciated,
despite studies revealing an increasingly tight connection with mutation of VHL. As
discussed above, VHL mutation provides a permissive setting for the deregulation of HIF
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family members, notably HIF-1α and HIF-2α [189]. Tumors can be classified, therefore,
into tumors expressing both factors (H1H2) or those expressing only HIF-2α (H2), or a
smaller number that produce a functional pVHL [69]. These definitions demonstrate distinct
patterns of gene expression and signal transduction, and suggest that HIF profile may be
important for selecting therapy. This method of subclassifying ccRCC tumors has been
hindered by assay inconsistency for the highly labile HIF proteins. Future studies may be
best served to consider a transcriptionally based instrument for assigning H1H2 vs H2
status.
Indeed, ccRCC provides an outstanding tumor model for expression-based analyses, and
numerous groups laid the groundwork for defining the heterogeneity of this tumor
classification based on transcriptional measurements. Studies based on supervised gene
expression profiling of primary tumors vs metastases, early vs late recurrences, or short vs
long survival have consistently shown differentially expressed genes [179, 190, 191].
Recently, Rini, et al reported on a transcriptional profile indicative of poor risk for
recurrence developed from paraffin embedded specimens[192], which indicates that
expression-based biomarkers are ready for translation to the clinic for prospective
evaluation.
In parallel, several groups have performed unsupervised analyses to determine if inherent
subtypes exist within ccRCC that can be defined based on purely molecular means [193,
194]. Two primary subgroups are found in relatively equal abundance in unselected tumors,
suggesting that ccRCC may be represented by two major subclassifications, termed ccA and
ccB in recent analyses [195]. The ccA and ccB subclassifications share many similarities to
the gene sets identified in good risk or poor risk tumors described above, respectively, in
particular gene sets involved in local invasion, and epithelial to mesenchymal transition.
Moreover, when the clinical outcomes are examined, ccA cases display a long median
survival of 8.6 years, whereas their ccB counterparts display median survival of only 2 years
(p=0.002). The advantages these emerging strategies of subclassification include the
potential to assign the profile of an individual tumor; capture of molecular information
which is tied to genetic events which may be critical for selection of targeted therapy; and
prognostic models which also consider clinically intermediate disease categories. A recent
validation by meta-analysis confirmed the presence of these ccA and ccB subtypes, but
further identified a subset defined by gene expression indicative of a wild type VHL and
variant histology consistent with the newly described clear cell papillary subtype [196, 197].
In spite of the hurdles ahead, it seems likely that molecular strategies to classify individual
tumors are on the horizon (Figure 6). In fact, the emerging data from clinically supervised
strategies to find risk-associated biomarkers, and molecularly driven strategies to identify
patterns within unselected tumors suggest that these two differing top-down, and bottom-up
approaches are converging on the same conclusion: That ccRCC is composed of two
dominant subgroups, which are closely aligned with clinical outcome. How this information
will enable physicians and patients to make wise decisions in the management of ccRCC, or
eventually select optimal pharmaceutical therapy remains to be seen, but in the light of many
emerging targeted therapies, such information is likely to be highly valuable.
BIOMARKERS
The modern emergence of therapeutic options based on the increased understanding of the
genetics and molecular biology of the RCC group of diseases has intensified the need for
biomarkers to accurately assess prognosis, identify patients likely to benefit from therapy
and specific drugs or classes of drugs, and understand mechanisms of resistance. Here we
present a succinct overview of the most recent advances in the development of biomarkers
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for RCC, in particular for the clear cell subtype. Although some are promising, it is
important to note that none of these biomarkers are available for clinical testing.
In clinically localized ccRCC, the emphasis has been placed on biomarkers of prognosis
expressed in tumor tissue. Some have been found independently prognostic, such as the
HIF-1α-regulated hypoxia marker carbonic anhydrase IX [198], the antiapoptotic protein
survivin [199–202], the cell proliferation protein KI-67 [203–206], and the immune
inhibitory family of ligands B7-H [207–209], but their clinical value is still in question due
to lack of independent and prospective validation. IMP3 (one of the insulin-like growth
factor II mRNA binding proteins), whose immunohistochemical expression in tumor cells
was found associated with short metastasis-free and OS, is a rare exception since findings
were subsequently validated in an independent patient cohort [210, 211].
Cytogenetic and gene expression profiling studies have also shown some potential to deliver
prognostic information in non-metastatic ccRCC. In mostly small cohorts of patients,
specific chromosomal abnormalities have been linked to good (5q gain) or poor prognosis
(9p, 14q loss) [212–214]. However, the relation of 9p loss with poor outcome including
prognostic value for small renal masses has been repeatedly observed [215, 216], making
this a logical candidate to incorporate to available prognostic algorithms. A number of
potential biomarkers related to tumor development and progression have additionally
emerged from gene expression analyses, several of which have identified gene signatures
associated with significant survival differences in patients [217–219]. However, as with the
immunohistochemical and cytogenetic markers, these signatures have not yet been
validated. Work to validate these gene signatures to predict risk of recurrence is ongoing.
In patients with advanced ccRCC, the availability of effective treatments targeting the
VEGF and mTOR pathways has shifted the focus towards the search of biomarkers,
predominantly in tumor tissue but also blood, capable of predicting therapy response and
resistance. While the analysis of VHL gene status has not resulted in consistent data to
support either a prognostic or predictive value [220–224], the activation state of the HIF
subunits [69] and multiple HIF-responsive genes are being examined. One HIF target,
VEGF, and other angiogenesis-related and tumorigenic factors in serum or plasma have
been evaluated across multiple clinical trials of targeted agents in RCC. It has been
established that higher baseline VEGF levels are associated with worse tumor stage and
grade, performance status, and overall prognosis [225–230]. Moreover, in a phase III trial of
sorafenib v placebo, patients with VEGF in the highest concentration quartile obtained
greater relative benefit from sorafenib than those with lower concentrations [230]. However,
studies addressing whether VEGF is a predictive marker for identifying RCC patients likely
to benefit from VEGF-targeted therapies have yielded inconsistent results [225, 230, 231].
Preliminary evidence supports the premise that proteomic plasma profiling of cytokines and
angiogenic factors (CAFs) in plasma or serum may be used to develop prognostic and
predictive biomarkers, and potentially also contribute to molecularly improve RCC
classification [232]. Using this approach, two broad groups of metastatic ccRCC patients
were identified, one predominantly expressing angiogenesis/hypoxia-related markers and a
second one showing an alternative expression of inflammatory markers. Regarding clinical
benefit by VEGF inhibitors, a recent study in plasma samples collected in subsequent phase
II and III studies of pazopanib identified low concentrations of IL-8, HGF, OPN and
TIMP-1 with improved PFS on pazopanib [233]. IL-8 had previously been implicated in
resistance to sunitinib [234]. Unfortunately, no biomarkers predictive of differential benefit
between available and active drugs in RCC have been validated. In a randomized phase II
study of sorafenib v sorafenib in combination with interferon that yielded no differences in
PFS, a candidate 6-CAF signature consistent of markers in the angiogenic/hypoxia group
(OPN, VEGF, collagen-IV, soluble CAIX, TRAIL, soluble VEGF receptor-2) predicted for
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distinct PFS in the 2 arms [232]. Results of similar analyses in larger patient sets are eagerly
awaited.
IMMUNOTHERAPY
The ability of some renal tumors to evoke an immune response and the possibility that this
may lead to spontaneous regression of metastatic renal cell carcinoma (RCC) in some
patients have spurred the idea of developing immunotherapy as an effective treatment for
patients with RCC [235–237]. Various immunotherapeutic strategies have been tested with
many showing some evidence of activity [238, 239]. Established therapies consist of
cytokines such as interferon alpha (IFN) and interleukin 2 (IL-2). IFN was reported to
provide a survival benefit in a meta-analysis [240]. HD IL-2 has produced tumor responses
in ~10–20% of patients with some patients achieving long-term response off treatment
[241–245] The FDA approved HD IL-2 as treatment for metastatic RCC in 1992 based on
Phase II data [241]. However, both IFN and HD IL-2 are associated with substantial
toxicities, which have limited their use [246, 247]. In addition, due to the emergence of
novel VEGF and mTOR targeted therapies, which are easier to administer, better tolerated
and proven to provide clinical benefit in Phase III clinical trials [248, 249], the use of IFN
and HD IL-2 as treatment for metastatic RCC has diminished. However, a subset of patients
clearly exists who develop significant clinical benefit from immunotherapy. Efforts are
ongoing to understand the mechanisms of action and identify predictors of response to
cytokine therapies such as IFN and HD IL-2 in an attempt to better select patients for
treatment. In addition, novel immunotherapeutic strategies are being developed due to
advances in the field of basic immunology, which have provided strong scientific and pre-
clinical data to enable successful immunotherapy trials.
Improved understanding of various mechanisms by which T-cell activation can be positively
or negatively regulated (Figure 7) has led to the development of agents which can enhance
anti-tumor T cell responses. The first such agent, and prototype, is anti-CTLA-4 antibody,
which laid the foundation for the development of other immune checkpoint agents such as
anti-PD-1 antibody.
Upon engagement of T cell receptor with antigen bound by MHC (signal 1) and co-
stimulation provided by CD28 interacting with B7-1 and B7-2 (signal 2), T cells become
activated to produce cytokines and proliferate[250, 251]. However, T cell activity must be
regulated in order to prevent damage to normal cells and tissues. Therefore, when T cells are
turned ‘on”, a series of signals within the cells also generate an “off” mechanism. This “off”
switch is known as CTLA-4. CTLA-4 acts to limit T cell responses [252, 253]. The
understanding of how CTLA-4 functions led to the idea that an antibody that blocks
CTLA-4, thereby temporarily disengaging the “off” switch, would allow for enhanced T cell
responses against tumors. This idea was validated in pre-clinical models [254, 255] and then
tested in clinical trials [256–258]. Two Phase III randomized clinical trials were completed
and documented a survival benefit for patients with metastatic melanoma who were treated
with the anti-CTLA-4 antibody known as ipilimumab (Bristol-Myers Squibb)[259, 260].
Based on these data, ipilimumab was recently FDA-approved in March 2011 as treatment
for patients with metastatic melanoma. Since anti-CTLA-4 targets a molecule expressed on
T cells, as opposed to a molecule on tumor cells, this therapy is potentially applicable to
multiple tumor types.
Anti-CTLA-4 has been evaluated in patients with metastatic RCC. In a Phase II trial, two
cohorts of patients with advanced RCC received two different dosing schedules of
ipilimumab: a 3mg/kg loading dose followed by either 1mg/kg or 3mg/kg maintenance
doses every 3 weeks [261]. Of the 21 patient receiving the 1mg/kg maintenance dose, one
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patient (4.7%) experienced a partial response. Of 40 patients treated with the 3mg/kg
maintenance dose, 5 (12.5%) experienced partial responses. Importantly, responses were
observed in patients who had failed prior HD IL-2 suggesting that there is no clear cross
resistance. Given its recent FDA approval for melanoma, ipilimumab will likely be
investigated further in patients with RCC.
PD-1 is another receptor that is expressed on activated T cells [262]. Interactions with PD-1
and its ligands (PD-L1 and PD-L2) can act to inhibit T cell responses. PD-L1 was shown to
be over-expressed in many RCC and greater expression was associated with worse
prognosis [263]. MDX-1106 is a monoclonal antibody directed against PD-1 which was
recently assessed in Phase I trials including many patients with advanced RCC[264, 265].
Anti-tumor activity was seen in a patient with RCC in the initial trial involving a single dose
of the PD1antibody[264]. In a subsequent study [265], MDX-1106 was administered in
doses of 1, 3, and 10mg/kg given every 2 weeks. Of 16 patients with RCC treated at various
doses, 5 patients (31%) achieved objective responses, including one complete response. This
promising activity coupled with a mild toxicity profile has prompted the initiation of a phase
II trial MDX-1106 in patients with advanced RCC. Over the next several years, agents such
as ipilimumab and MDX-1106 will likely be assessed, possibly with cytokines and other
therapies, in various sequences and combinations with the goal of achieving higher rates of
durable responses than is possible with currently available therapies.
MOLECULARLY TARGETED THERAPY
The biology of RCC as elucidated above has led to the development of multiple agents
targeting elements of the relevant VEGF and mTOR pathways [266]. Table 1 outlines that
major phase III trials of targeted therapy in RCC that have led to regulatory approval of
several agents. There are several points to be made about key discriminating features of
these agents. VEGF-targeted therapy produces more robust RECIST-defined objective
response rates than cytokine therapy, on the order of 30% to nearly 50% for the most active
agents. Within the class of VEGF receptor inhibitors, the response rate can vary from 10%
to nearly 50%, with the higher rates observed with the drugs that more potently inhibit the
VEGF-Receptor. It is also recognized that anti-tumor activity, especially of VEGF-targeting
agents, is not entirely captured by size changes alone, as tumor necrosis (reduced perfusion
on a contrast-enhanced CT scan) is felt to be indicative of drug effect and may or may not be
accompanied by tumor size reduction. mTOR-targeted therapy in general produces more
modest response rates of 2–10%, although to date studied in different populations than the
VEGF-targeted therapies [267, 268]. When considering the percentage of patients who have
at least some tumor burden reduction on therapy (i.e. including patients with 1%-29%
reduction not meeting the arbitrary 30% reduction required for a RECIST-defined response),
VEGF-targeted therapy shrinks tumors in about 75% of patients while mTOR-targeted
therapy shrinks tumors in about 50–60% of patients.
Progression-free survival is generally doubled with targeted therapy compared with placebo/
cytokines. Again, here we see important differences among the VEGF-R inhibitors, with the
biochemically more potent agents producing a PFS of approximately 11 months in untreated
patients, compared to 5 months for the biochemically weaker agent, sorafenib. Axitinib is
the most biochemically potent, but to date results are only available in previously-treated
patients [269]. Of note, in the subset of patients not exposed to prior VEGF-targeted therapy
in the AXIS trial (the cytokine-refractory subgroup), the median PFS was over 12 months.
In regards to PFS, the mTOR-targeting agents have been studied in unique patient
circumstances, poor-risk for temsirolimus and VEGF-R TKI-refractory RCC for everolimus
[267, 268]. The PFS in each was modest (approximately 5 months), but the effect of these
agents front-line in good/intermediate risk patients awaits further study. In addition, the
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clinical activity of drugs is more robust in untreated patients than in cytokine-refractory, and
even less in patients who have already failed targeted therapy. Last, overall survival in these
trials is of note for several reasons. The front-line trials of VEGF-targeted agents have
produced an OS of approximately 2 years, roughly double that of historical cytokine-treated
controls. Nonetheless, no single trial (with the exception of the temsirolimus trial in poor
risk RCC) has shown a statistically significant overall survival benefit (despite a numerical
advantage in the median OS). This is largely felt to be due to the high percentage of patients
who cross over from initial therapy on trial (placebo or cytokine) and receive one or more
active targeted therapies at progression. The efficacy of such a sequential ‘salvage’ strategy
has confounded interpretation of OS from these trials, although there is general consensus
that targeted therapy has meaningfully extended the lives of metastatic RCC patients.
There is no consensus on the ‘best’ drug for initial therapy or the optimal sequence of
agents. Ongoing trials are beginning to approach these questions, but the multitude of agents
and the relative rarity of RCC make definitive trials not possible. Future research in targeted
therapy in RCC is focused on such questions of relative toxicity/efficacy among agents, the
importance of switching mechanism at progression, and biomarkers of response and
resistance that may allow for improvement upon the current standard of an empiric sequence
of monotherapies.
CONCLUSIONS
There has been a clear and important evolution in our understanding of RCC biology. We
are now challenged with converting this newly acquired information into actionable items
that will alter our approach to prevention, diagnosis and management of RCC. Several new
rare types of cancers are now recognized to occur in the kidney, which will both challenge
the urologic oncology community to maintain up-to-date guidelines for the management of
these tumors and provide new opportunities to develop effective personalized therapies.
By comparing genomic, transcriptomic and epigenetic data from precursor lesions and early
ccRCC, we will be able to establish a roadmap of tumor ontogeny for this more common
subtype. Use of material from patients with hereditary VHL disease will be essential to
achieve this goal. These data, in conjunction with epidemiological and laboratory based
studies, will allow the investigator to identify driver mutations and epigenetic changes,
allowing development of markers that permit early identification of ccRCC. In the same
manner, study of the cilia centrosome cycle and HIF regulation will build a mechanistic,
molecular biological understanding of early cancer development, with resultant
opportunities for therapeutic intervention.
In more advanced disease, the study of genomics, transcriptomics and molecular biology
will provide investigators with insight into mechanisms of tumor progression, especially if
performed in parallel with in vitro and in vivo models employing potential driver pathways
identified in ccRCC or other rare variant cancers. The hope is that by understanding both the
cause and the consequence of the complex interactions between genomic and epigenetic
changes, and assigning significance to the output of these alterations, we will be able to
replicate RCC tumor diversity, identify subgroups, and develop more specific therapeutic
interventions. To achieve this goal will require coordinated interaction between high-
throughput platform experts, molecular biologists and computational scientists capable of
controlling and codifying the complex systems that arise from these collaborations. The
recognition that the output of these changes is profoundly influence by host genomic and
phenotypic characteristics, and that the tumor microenvironment varies as a function of
these characteristics requires the development of precise tools to measure the tumor
microenvironment.
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Finally, the renaissance of tumor immunology was fueled by the recognition that tumors can
take advantage of the innate regulatory pathways built into T-cells and other immune
effectors. As we begin to understand the impact of tumor biology on T-cell regulation as
well as on the recruitment of bone marrow derived immunological precursors, significantly
better treatments will become available for patients with ccRCC in the next few years.
Understanding the interface between evolving tumor biology and host genomic determinants
of stromal end endothelial phenotype will further advance this field.
We are poised to make very significant advances in RCC research in the next few years.
With the right team and the right tools, the potential for a truly personalized approach to
treatment is within reach.
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Figure 1. Overview of Histone 3 modifications implicated in RCC genetics
A number of histone modifying genes are mutated in renal cell carcinoma. These include the
H3K36 trimethylase SETD2, the H3K27 demethylase UTX/KDM6A, the H3K4
demethylase JARID1C/KDM5C and the SWI/SNF complex compenent PBRM1, shown in
this cartoon to represent their relative activities on Histone H3.
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Figure 2. pVHL mutants are categorized as Class A, B and C depending on the affected step in
pVHL protein quality control
VHL proteostasis involves the chaperone mediated translocation of nascent VHL peptide
from the ribosome to the TRiC/CCT chaperonin, where folding occurs in an ATP dependent
process. The VBC complex is formed while VHL is bound to TRiC, and the mature complex
is then released. Three different classes of mutation exist: Class A mutations prevent binding
of VHL to TRiC, and abrogate folding into a mature complex. Class B mutations prevent
association of Elongins C and B to VHL. Class C mutations inhibit interaction between
VHL and HIF1 a.
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Figure 3. Immunofluorescent images of primary cilia in VHL+ and VHL− cells
Immunofluorescent images of primary cilia in VHL+ and VHL− cells using ciliary marker
alpha-acetylated-tubulin (red) and centrosomal marker antipericentrin (green),
counterstained for DNA with DAPI (blue). Left panel shows three color merge VHL+ cells;
right panel demonstrates the absence of cilia in VHL− cells. Individual cells are color coded
by various shades of gray; cilium (red) and associated basal bodies (green) are also
segmented by automated image analysis.
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Figure 4. Regulation of Prolyl Hydroxylases and Keap1 by Krebs cycle
Regulation of Prolyl Hydroxylases by Tricarboxylic Acid (TCA) Cycle Intermediates. Prolyl
hydroxylases use TCA cycle intermediates to help catalyze the oxygen, iron and ascorbate
dependent- addition of a hydroxyl side chain to a Pro402 and Pro564 of HIF alpha subunits,
leading to VHL binding and degradation. Defects in either fumarate hydratase or succinate
dehydrogenase will drive up levels of fumarate and succinate, which competitively bind
prolyl hydroxylases, and prevent HIF prolyl hydroxylation. This results in higher
intracellular HIF levels.
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Figure 5. Regulation of mTORC1
HIF regulation and mTOR pathway connections. Hypoxia blocks HIF expression in a
TSC1/2 and REDD dependent pathway [155]. HIF1α appears to be both TORC1 and
TORC2 dependent, whereas HIF2α is only TORC2 dependent [275]. Signaling via TORC2
appears to upregulate HIF2α in an AKT dependent manner [69].
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Figure 6. Subtypes of clear cell and papillary RCC, and a new subtype, clear cell papillary
Different subtypes of clear cell RCC can be defined by HIF patterns as well as by
transcriptomic expression as defined by ccA and ccB subtypes. Papillary RCC also
demonstrates distinct histological subtypes. A recently described variant denoted as clear
cell papillary RCC is VHL wildtype (VHL WT), while other clear cell tumors are
characterized by VHL mutation, loss, or inactivation (VHL MT).
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Figure 7. T cell regulation in RCC
Immune regulation of renal tumor cells. A: When an antigen presenting cell (APC) engages
a T-cell via a cognate T-cell receptor (TCR) and CD28, T-cell cell activation occurs. B:
Early and late T-cell inhibitory signals are mediated via CTLA-4 and PD-1 receptors, and
this occurs via engagement of the APC via B7 and PD-L1, respectively. C: Inhibitory
antibodies against CTLA-4 and PD-1 can overcome T-cell downregulation and once again
allow cytokine production.
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